Quethera Ltd, a Cambridge, UK-based gene therapy company, obtained a grant from the Wellcome Trust Pathfinder Award Scheme.
The award will assist the company in the optimization and design of its novel gene construct aimed at preventing further sight loss in patients with glaucoma.
Founded in 2013 by Dr Peter S. Widdowson, CEO, and Keith Martin, Professor of Ophthalmology at the University of Cambridge, Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. The initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve.
Based at the Babraham Research Campus, the company received seed funding last year from the Rainbow Seed Fund and Cambridge Enterprise, the commercialization arm of the University of Cambridge.